Author

Fabio Molina Morales

OpenAlex ID: A5113060654

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

2023 · Lisa Giulino Roth, Frank Keller, et al. · Blood · 5

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

2024 · Lisa Giulino Roth, Mario Melgar Toledo, et al. · Blood

Works count: 2

Citation count: 5

H-index: 1

I10-index: